

Press Release November 2007

Agreement with Novartis Pharma AG (Switzerland)

RohnerChem (Pratteln, Switzerland) has agreed with Novartis Pharma AG (Switzerland) to custom manufacture an intermediate compound to be tested in clinical development. This exclusive supply agreement further attests to RohnerChem's positioning in selected market segments, where complex, multi-step, and innovative synthesis is required.

RohnerChem focuses on custom synthesis for speciality and fine chemicals and full service for the life science industry. Today, the company offers the production of Advanced Intermediates and Active Pharmaceutical Ingredients (APIs) on an exclusive basis for customers in the pharmaceutical industry. All production is carried out according to ISO and, as needed, according to cGMP standards on lab or large scale. RohnerChem is to provide fast and cost efficient technology transfer into its complex multipurpose plants in short timeframes and is therefore an interesting manufacturing partner.